CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2020—The U.S. Food and Drug Administration announced the approval of Ervebo (Merck), the first FDA-approved vaccine for the prevention of Ebola virus disease, caused by Zaire ebolavirus, in people 18 years of age and older. Ervebo is administered as a single-dose injection and is a live, attenuated vaccine that has been genetically engineered to contain a protein from the Zaire ebolavirus.
The FDA granted this application priority review and a tropical disease priority review voucher as well as a breakthrough therapy designation.
Pages: 1 2